

Magnesium intervention during pregnancy

Submission date 23/08/2010	Recruitment status No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 14/09/2010	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 05/11/2014	Condition category Pregnancy and Childbirth	<input type="checkbox"/> Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Prof Ragnar Rylander

Contact details
Bjorkasvagen 21
Lerum
Sweden
443 91
+46 (0)708 40 0101
envhealth@biofact.se

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers
N/A

Study information

Scientific Title

Acid-base balance and blood pressure during pregnancy: a double-blinded randomized controlled trial

Study objectives

Intervention with magnesium citrate will prevent increase in blood pressure during last part of pregnancy.

Further reading: <http://www.ncbi.nlm.nih.gov/pubmed/20135136>.

Ethics approval required

Old ethics approval format

Ethics approval(s)

The Gothenburg Committee, 08/03/2009, ref: 098-09

Study design

Double blind interventional randomised controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Prevention

Participant information sheet

Not available in web format, please use contact details below to request a patient information sheet

Health condition(s) or problem(s) studied

Pregnancy

Interventions

Magnesium citrate powder (Diasporal), 12 mmol magnesium daily, taken at week 25 of pregnancy until delivery.

Control group receive no supplements. Blood pressure and proteinurea are measured routinely in all pregnancies

Intervention Type

Other

Phase

Not Applicable

Primary outcome measure

Blood pressure increase during final weeks of pregnancy

Secondary outcome measures

Symptoms of pre-eclampsia during final weeks of pregnancy

Overall study start date

01/10/2010

Completion date

01/10/2012

Eligibility**Key inclusion criteria**

1. First time pregnancies
2. Urinary calcium excretion in excess of 6 mmol around pregnancy week 20

Participant type(s)

Patient

Age group

Adult

Sex

Female

Target number of participants

60

Key exclusion criteria

History of blood pressure or renal dysfunction

Date of first enrolment

01/10/2010

Date of final enrolment

01/10/2012

Locations**Countries of recruitment**

Sweden

Study participating centre

Bjorkasvagen 21

Lerum

Sweden

443 91

Sponsor information

Organisation

Sodra Alvsaborgs Hospital (Sweden)

Sponsor details

Maternity care unit

Boras

Sweden

501 82

+46 (0)33 616 0000

Mats.elm@vgregion.se

Sponsor type

Hospital/treatment centre

ROR

<https://ror.org/01qas6g18>

Funder(s)

Funder type

Research council

Funder Name

South Alvsborg Research and Development Council (Forskning och Utveckling [FoU]) (Sweden)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/12/2013		Yes	No

